Safety Study of Carbamylated Erythropoietin to Treat Patients With the Neurodegenerative Disorder Friedreich's Ataxia
Status:
Completed
Trial end date:
2011-04-01
Target enrollment:
Participant gender:
Summary
The primary purpose of the study is to determine whether carbamylated erythropoietin is a
safe treatment for patients who suffer from Friedreich's Ataxia.